Rheumnow Podcast

Can we alter neonatal gut microbiome to prevent spondyloarthritis? Dr Chao discusses Abstract 0868 at the ACR22 Convergence meeting.  Abstract 0868: Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome JAK vs TNF inhibitor Infections in RA Dr. David Liew discusses abstract 0302 at ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis Opioid and Neuropathic Use After Initiating btsDMARDs in RA Dr. Julian Segan discusses Abstract 0925 at the ACR22 Convergence meeting. The Dietary Intervention in PsA (DIPSA) StudyDr. Patricia Harkins talks with Professor Lihi Eder about abstract 1007 at the ACR22 Convergence meeting.  Abstract 1007: Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study Treatment Considerations in Axial Spondyloarthritis Dr. Lianne Gensler discusses treatment considerations in Axial SpA. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS Abstract 0388: Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States Abstract 0544: Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study Abstract 0545: Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatment in Patients with Non-radiographic Spondylarthritis Who Achieved Inactive Disease: Efficacy and Safety Results from a Placebo-Controlled, Randomized Withdrawal and Retreatment Study (GO-BACK) What lifestyle factors affect TNF inhibitor efficacy in AxSpA? Dr Chao discusses Abstract 1510 at ACR22 Convergence. Abstract 1510: Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries    

2023 RWCS Meeting Dr. Arthur Kavanaugh invites you to join him for the 2023 RWCS meeting in February 2023. Dr David Liew JAK inhibitor VS TNF inhibitor, Infections in East Asian Patients. Abstract 302 Early Diagnosis of Axial Spondyloarthritis Dr. Antoni Chan talks with Dr.  Nelly Ziade at ACR22 Convergence in Philadelphia, PA. Abstracts 1512: What Is the Best Referral Strategy for Axial Spondyloarthritis? A Prospective Multicenter Study of 515 Patients with Suspicious Chronic Low Back Pain Abstract 1517: Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain New Treatments for SLE? Dr. Michelle Petri discusses abstract 1117 presented at ACR22 Convergence meeting in Philadelphia, PA.  Abstract 1117: Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

ACR2022 Daily Recap for Saturday, November 12th.

Breakthrough COVID infection in SLE during Omicron era Dr. Yusof talks with Dr. Amit Saxena about abstract 2081 at ACR22 Convergence. Abstract 2081: COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave Differences in Presentation and Outcomes of Early vs Late Onset PsA Dr. Olga Petryna discusses abstract 0377 presented at ACR22 Convergence. Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies

A Year in Review Dr. Jack Cush, Philadelphia Differences in Clinical Presentation and Outcomes of Early vs Late Onset PsA Dr. Olga Petryna, New York Abstract 0377 mTORC1 as a Driver of Inflammation in sJIA Connecting Pathogens of sJIA and MAS Dr. Olga Petryna, New York Abstract 0004 Patient Reported Outcomes in PsA Using Novel IL 17A Inhibitor Dr. Sims discusses abstract 0199 presented at ACR22 Convergence in Philadelphia, PA. Abstract 0199: Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis The CONSUL Trial Dr. Sheila Reyes, The Phillipines Abstract 0526  

Best of PsA on Day 1 Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence.  Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies Can computers tell the difference between RA & PsA? Dr. David Liew discusses Abstract 0242 presented at ACR22 in Philadelphia, PA. Abstract 0242: Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging Can you use the BASDAI in Pregnancy? Dr. Eric Dein discusses abstract 0374 presented at ACR22 Convergence in Philadelphia, PA. Abstract 0374: The BASDAI Index During Pregnancy Drs Tate and Worthing What's going on on the Hill Session # 12S119. Effect of voclosporin in class V lupus nephritis Dr. Yusof discusses abstract 0355 presented at ACR22 Convergence in Philadelphia, PA.  Abstract 0355: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study Microbiome and AxSPA Dr. Akhil Sood discusses abstract 1162 presented at ACR22 Convergence in Philadelphia, PA.  Abstract 1162: Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthritis After One Year of Biological Treatment Opioids and Health Care Utilization in PsA and AS Dr Aurelie Najm  discusses Abstract 0402 presented at ACR22 Convergence in Philadelphia, PA. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS Switching Between JAK Inhibiters in RA Dr. Janet Pope discusses abstract 0274 presented at ACR22 Convergence in Philadelphia, PA.  Abstract 0274: Real-world Utilisation and Switching Between Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in the Australian OPAL Dataset Treatment Choices and Mortality in RA ILd 2 Dr. Julian Segen, Philadelphia Dr. Bryant England, Philadelphia Upadacitinib vs  Adalimumab in PsA using RAPID3 Dr. Catherine Sims discusses abstract 0192 presented at ACR22 Convergence.  0192: Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis      

Frailty in Vasculitis Dr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at ACR22 Convergence. Lupus, Sex and STDs Dr. Kathryn Dao discusses abstract 0939 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0939: Pilot Study: A Novel Method for Cervical Health Monitoring in African American Women with Systemic Lupus Erythematosus (SLE) Using a Self- Sampling Brush to Assess Cervical HPV Infection and Cervical Cytology Much gusto for GUSTO: Efficacy of Tocilizumab Monotherapy for Giant Cell Arteritis Dr. Richard Conway discusses abstract 0470, being presented during Poster Session A on Saturday, November 12, 2022 at the ACR 2022 meeting.  Abstract 0470: Long-term Efficacy of Tocilizumab Monotherapy After Ultra-short Glucocorticoid Administration to Treat Giant Cell Arteritis – One Year Follow-up of the GUSTO Trial NSAIDs and CV risk in Inflammatory Arthritis Dr. Richard Conway discusses abstract 1207, being presented during Poster Session C on Sunday, November 13, 2022 at the ACR 2022 meeting.  Abstract 1207: Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid Should You Repeat the ENA Panel? Dr. Kathryn Dao discusses abstract 0725, presented at ACR22 Convergence.  Abstract 0725: Utility of Repeat Extractable Nuclear Antigen Antibody Testing- a Retrospective Audit To Beta Block or Not in GCA and Large Vessel Vasculitis Dr. Patricia Harkins discusses abstract 0477 presented on Saturday, November 12, 2022, at ACR22 Convergence. Abstract 0477: Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis? A Novel Treatment Response Measurement Tool for Lupus Dr. Kathryn Dao discusses abstract 2054 with Dr. Eric Morand at the ACR22 Convergence meeting. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process Sarilumab in Polymyalgia Rheumatica: Results from Phase 3 Trial Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA.  Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) Welcome to ACR 2022 Dr. Jack Cush, Executive Editor of RheumNow, welcomes you to Philadelphia for ACR22 Convergence! 2022 ACR/EULAR Classification Criteria for GCA Dr. Michael Putman discusses interesting take-home messages from the Vasculitis Investigators Meeting at ACR22 Convergence regarding the 2022 ACR/EULAR Classification Criteria for GCA. Gender in AxSpa Dr. Peter Nash, Philadelphia Do Disease Activity Measures Really Capture AS in Women? Dr. Rachel Tate interviews Dr. Sinead Mcguire about Abstract 0406, presented at ACR22 Convergence in Philadelphia, PA. Abstract 0406: https://acrabstracts.org/abstract/are-the-basdai-basfi-capturing-the-full-impact-of-disease-activity-on-quality-of-life-in-women-with-axial-spondyloarthritis/ Dr Aurelie Najm  Opoids and health care utilization in PsA and AS Abstract 402 Poor Medication Adherence in SLE  and How to Improve It Dr. Janet Pope discusses three abstracts presented at the ACR22 Convergence meeting in Philadelphia, PA. 0343: Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort 0115: Facilitators of Immunosuppressive Medication Adherence in Systemic Lupus Erythematosus: A Qualitative Study of Racial Minority Patients, Lupus Providers and Clinic Staff 0063: Implementability of a SLE Medication Adherence Intervention Sputum anti-CCP the new diagnostic test in at-risk RA? Dr. Aurelie Najm discusses abstract 0533 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0533: Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity Drs Cush and Fava:  Urinary Biomarkers in Lupus Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria Social Media in Rheumatology Academia Dr. Kathryn Dao, Dallas Jorena Lim, third-year medical student, UTSW, Dallas Abstract 0220 Treatment Choices and Mortality in RA ILd Dr. Julian Segen, Philadephia Dr. Bryant England, Philadephia Dr Tate PsA Cycling or Switching MOAs with Dr  Ogdie Abstracts 1600 and 402. Dr Cassy Sims The Impact of Upacitinib vs  Adalimumab in Psoriatic Arthritis using RAPID Abstract 192. Urinary Biomarkers in Lupus Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria Dr Janet Pope Switching from a JAK Inhibiter Abstract 0274. Dr Yusof Effect of voclosporin in Class 5 lupus nephritis Abstract 0355. Best of PsA Dr. Rachel Tate Drs Yusof and Sexena Breakthrough COVID infection in a lupus cohort during Omicron era Session # 12S119. PsA Cycling or Switching MOAs Dr. Rachel Tate interviews Dr. Alexis Ogdie at ACR22 Convergence in Philadelphia, PA.  Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Abstract 402: Opioid Use and Healthcare Utilization in Adults with PsA and AS Urine Proteomics in SLE with Dr. Michelle Petri Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at ACR22 Convergence.

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com and looks forward to highlight sessions in the next few days at ACR Convergence 2022.

QD201 - Seropositive Arthralgia (abstract #1604)   https://youtu.be/uQt_IV3FmZc QD202 -1st Line Anakinra (abstract #L12)    https://youtu.be/QyDVQBnYqn4 QD203 - When to Worry About Malignancy and Myositis (abstract #002)   https://youtu.be/qt-debWfSrY QD204 How to Treat Erosive OA (abstract #L05)    https://youtu.be/5-atRyBsCn4 QD205 - RA Activity During Pregnancy (abstract #0955)    https://youtu.be/wavTWqZbhq4 

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.  New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?